Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
The historical rank and industry rank for Procter & Gamble Health's OCF Margin % or its related term are showing as below:
BOM:500126'
s OCF Margin % Range Over the Past 10 Years
Min: -15.94 Med: 13.15 Max: 24.96
Current: 16.21
During the past 13 years, the highest OCF Margin % of Procter & Gamble Health was 24.96%. The lowest was -15.94%. And the median was 13.15%.
BOM:500126's OCF Margin % is ranked better than 68.71% of 962
companies
in the Drug Manufacturers industry
Industry Median: 10.035
vs BOM:500126: 16.21
Procter & Gamble Health OCF Margin % Related Terms
Procter & Gamble Health OCF Margin % Historical Data
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Drug Manufacturers - Specialty & Generic subindustry, Procter & Gamble Health's OCF Margin %, along with its competitors' market caps and OCF Margin % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Procter & Gamble Health OCF Margin % vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Procter & Gamble Health's OCF Margin % distribution charts can be found below:
* The bar in red indicates where Procter & Gamble Health's OCF Margin % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Procter & Gamble Health (BOM:500126) has a OCF Margin % of 0.00% as of Mar. 2026. OCF Margin is the ratio of Cash Flow from Operations to Total Revenue. View historical data on Procter & Gamble Health and its competitors. According to the industry distribution chart, Procter & Gamble Health ranks #301 out of 962 companies in the Drug Manufacturers industry, placing it in the top 31.3%.
Is Procter & Gamble Health's OCF Margin % too high?
Procter & Gamble Health's current OCF Margin % is 0.00%. Based on the distribution chart, Procter & Gamble Health ranks #301 out of 962 companies in the Drug Manufacturers industry, which is above the industry midpoint. Overall, Procter & Gamble Health has a GF Score™ of 86/100 and is considered Modestly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Procter & Gamble Health's OCF Margin % compare to ZTS and UTHR?
According to the Drug Manufacturers industry distribution chart, Procter & Gamble Health ranks #301 out of 962 companies for OCF Margin %. This puts Procter & Gamble Health in the upper half of its industry. The industry median OCF Margin % is 10.04. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good OCF Margin % for a Drug Manufacturers company?
The median OCF Margin % among Drug Manufacturers companies is 10.04, based on 962 companies in the industry. Companies in the top quartile (top 25%) have a OCF Margin % significantly above this median, while those in the bottom quartile fall well below. However, OCF Margin % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high OCF Margin % mean?
A high OCF Margin % can signal that a stock is expensive relative to its fundamentals. OCF Margin is the ratio of Cash Flow from Operations to Total Revenue. View historical data on Procter & Gamble Health and its competitors. For the Drug Manufacturers industry, the median OCF Margin % is 10.04 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Procter & Gamble Health's current OCF Margin % is 0.00%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Procter & Gamble Health stock overvalued right now?
Based on GuruFocus' analysis, Procter & Gamble Health (BOM:500126) is currently considered Modestly Overvalued. The stock's GF Value™ is ₹6,049.27, compared to a current price of ₹6,797.90 — trading 12.4% above its estimated fair value. The current OCF Margin % is 0.00%. Procter & Gamble Health's overall GF Score™ is 86/100 with 6 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is OCF Margin % calculated?
OCF Margin % is calculated from a company's financial statements. For Procter & Gamble Health (BOM:500126), the current OCF Margin % is 0.00% as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Procter & Gamble Health (BOM:500126) Overvalued in 2026?
Based on GuruFocus' analysis, Procter & Gamble Health stock appears to be overvalued.
The current stock price of ₹6,797.90 is trading 12.4% above its estimated GF Value™ of ₹6,049.27.
GuruFocus considers Procter & Gamble Health to be Modestly Overvalued.
Key valuation signals for BOM:500126:
OCF Margin %: 0.00%
GF Value™: ₹6,049.27 vs. price of ₹6,797.90 (12.4% above fair value)
No single metric tells the full story. See the BOM:500126 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Procter & Gamble Health Ltd is an India based pharmaceutical company engaged in manufacturing and selling of healthcare products, viz., vitamins, minerals and supplements. Patients are end consumers of the products. The Company's distribution channels (direct & indirect), inter alia, include distributors, health care professionals, pharmacies and chemists. Cosome, Evion, Neurobion, Nasivion, Polybion, Livogen and Seven Seas are some of the brands of the company. The geographical segments include sales in India and exports.
86GF Score
Get the complete analysis for BOM:500126
OCF Margin % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
BOM:500126 has been successfully added to your 
